A Randomized, Double-blind, Multicenter Phase III Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of a Freeze-dried Formulation of MVA-BN Smallpox Vaccine in Healthy, Vaccinia-naive Subjects
Latest Information Update: 09 Jun 2024
Price :
$35 *
At a glance
- Drugs Modified vaccinia Ankara (Primary)
- Indications Smallpox
- Focus Pharmacodynamics; Registrational
- Sponsors Bavarian Nordic
- 31 May 2024 According to a Bavarian Nordic media release, Following a standard review time of 10 months for the sBLA, approval of the freeze-dried formulation could be obtained in the first quarter of 2025.
- 31 May 2024 According to a Bavarian Nordic media release, based on clinical data from a Phase 3 lot consistency study and data from a Phase 2 study, today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of a freeze-dried formulation of JYNNEOS for prevention of smallpox and mpox disease in adults 18 years of age and older.
- 29 Nov 2022 Results assessing the immunogenicity and safety of 3 consecutively produced lots of freeze-dried MVA-BN vaccine in healthy adults, published in the Vaccine.